What 6 Analyst Ratings Have To Say About ResMed
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on ResMed (NYSE:RMD) stock. The company has an average price target of $253.5, a decrease from the previous average price target of $270.20. The ratings include 1 bullish, 4 somewhat bullish, and 1 indifferent.
September 05, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ResMed's average price target has been lowered to $253.5 from $270.20, according to 6 analysts. The ratings are mostly bullish.
The average price target for ResMed has been lowered, which could indicate a potential downside. However, the majority of the ratings are bullish or somewhat bullish, which suggests a positive outlook. The indifferent rating adds some uncertainty, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100